Lessons from the Chinese Defective Vaccine Case.
Yiming Li,Zaiping Jing
DOI: https://doi.org/10.1016/s1473-3099(19)30062-3
2019-01-01
Abstract:With the withholding of problematic batches of rabies vaccine, ensuring that they are not placed on the market, judgements of accountability, such as deposing all involved administrators of the China Food and Drug Administration (CFDA),1People's Daily OnlineChina sacks six officials in defective vaccine case.http://en.people.cn/n3/2018/0818/c90000-9492072.htmlDate: Aug 18, 2018Date accessed: January 28, 2019Google Scholar and punishment of Changchun Changsheng Biotech, who were forced to pay about ¥9·1 billion (US$1·3 billion),2People's Daily OnlineVaccine maker Changsheng fined 9·1 billion yuan in safety scandal.http://en.people.cn/n3/2018/1017/c90000-9509011.htmlDate: Oct 17, 2018Date accessed: January 28, 2019Google Scholar by Oct 17, 2018, the Chinese public received an acceptable result in the defective vaccine case. This incident was first heard of after a tip-off from a member of staff at Changchun Changsheng Biotech on July 5, 2018. However, by this time the company had already been selling defective vaccines for 2 years. In 2016, a batch of rabies vaccine made defective by cold-chain failure3Fung IC Cheung CN Fu KW Vaccine safety and social media in China.Am J Infect Control. 2016; 44: 1194-1195Summary Full Text Full Text PDF PubMed Scopus (9) Google Scholar and worth ¥570 million was transported from Shandong province to 24 other provinces in China. In the same year, Changchun Changsheng Biotech had also made a batch of defective diphtheria-pertussis-tetanus (DPT) vaccine, which was identified by the CFDA at the end of 2017, but not dealt with until July 15, 2018. The investigation by the CFDA occurred nearly 9 months after a batch of more than 250 000 defective DPT vaccines was sold to Shandong province by Changchun Changsheng Biotech and a batch of more than 400 000 was sold to Chongqing city and Heibei province by Wuhan Vaccine and Serum Institute. In China, the public was not familiar with efficient advocacy methods. Although the Chinese Government is open to patient advocacy, and people can appeal to the government through the website of the State Administration for Market Regulation (name of the CFDA as of April 10, 2018), it took the CFDA 2 years from first use of the defective DPT vaccine in Shandong province in March, 2016, to investigate the event. Few groups or organisations that advocate for patients are well known. Most of the advocacy that occurs in China is a result of individual actions. Generally, it is difficult for people to get instant attention and enough official support for advocacy. Given the slow settlement of the defective vaccine case, a law supporting advocacy channels (especially for public health) in China is urgently needed. The Chinese medical environment has improved in the past few decades, and the Chinese Government continues to make efforts to improve it further. Since 2001, the National Health and Family Planning Commission of the People's Republic of China has abolished the drug-plus compensation mechanism, intensified the power of health supervision departments,4National Health and Family Planning Commission of ChinaChina health and health development statistics bulletin 2017.http://www.nhfpc.gov.cn/guihuaxxs/s10743/201806/44e3cdfe11fa4c7f928c879d435b6a18.shtmlDate: 2018Date accessed: January 28, 2019Google Scholar introduced a professional training policy after establishment of a standardised training system, and showed no tolerance towards violence against doctors.5People's Daily OnlineChina issues regulation to tackle violence against doctors.http://en.people.cn/n3/2017/0712/c90000-9240782.htmlDate: July 12, 2017Date accessed: July 12, 2017Google Scholar Moreover, after the defective vaccine case, a draft law on vaccine management aiming to tighten supervision of the industry was discussed at the 13th National People's Congress Standing Committee.6People's Daily OnlineYearender: legislations strive to address livelihood issues in 2018.http://en.people.cn/n3/2018/1228/c90000-9532599.htmlDate: Dec 28, 2018Date accessed: January 28, 2019Google Scholar The most important lesson that we should learn from this incident is that matters such as this need to be curbed before they become a real problem. We declare no competing interests.